[go: up one dir, main page]

SI2121630T1 - Antagonisti receptorja dopamin 2 s hitro disociacijo - Google Patents

Antagonisti receptorja dopamin 2 s hitro disociacijo

Info

Publication number
SI2121630T1
SI2121630T1 SI200830804T SI200830804T SI2121630T1 SI 2121630 T1 SI2121630 T1 SI 2121630T1 SI 200830804 T SI200830804 T SI 200830804T SI 200830804 T SI200830804 T SI 200830804T SI 2121630 T1 SI2121630 T1 SI 2121630T1
Authority
SI
Slovenia
Prior art keywords
receptor antagonists
fast dissociating
dissociating dopamine
dopamine
fast
Prior art date
Application number
SI200830804T
Other languages
English (en)
Inventor
Gregor James Macdonald
Xavier Jean Michel Langlois
Jose Manuel Bartolome-Nebreda
Gool Michiel Luc Maria Van
Original Assignee
Janssen Pharmaceutica, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38057298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2121630(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica, N.V. filed Critical Janssen Pharmaceutica, N.V.
Publication of SI2121630T1 publication Critical patent/SI2121630T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200830804T 2007-02-13 2008-02-11 Antagonisti receptorja dopamin 2 s hitro disociacijo SI2121630T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07102222 2007-02-13
EP08716791A EP2121630B1 (en) 2007-02-13 2008-02-11 Fast dissociating dopamine 2 receptor antagonists
PCT/EP2008/051597 WO2008098892A1 (en) 2007-02-13 2008-02-11 Fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
SI2121630T1 true SI2121630T1 (sl) 2012-12-31

Family

ID=38057298

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830804T SI2121630T1 (sl) 2007-02-13 2008-02-11 Antagonisti receptorja dopamin 2 s hitro disociacijo

Country Status (31)

Country Link
US (2) US8791120B2 (sl)
EP (1) EP2121630B1 (sl)
JP (1) JP5225292B2 (sl)
KR (1) KR101486408B1 (sl)
CN (1) CN101605764B (sl)
AR (1) AR065333A1 (sl)
AU (1) AU2008214716B2 (sl)
BR (1) BRPI0807492A2 (sl)
CA (1) CA2674752C (sl)
CL (1) CL2008000440A1 (sl)
CY (1) CY1113759T1 (sl)
DK (1) DK2121630T3 (sl)
EA (1) EA017508B1 (sl)
ES (1) ES2392470T3 (sl)
HR (1) HRP20120876T1 (sl)
IL (1) IL200310A (sl)
JO (1) JO2849B1 (sl)
MX (1) MX2009008616A (sl)
MY (1) MY148899A (sl)
NZ (1) NZ578560A (sl)
PA (1) PA8768901A1 (sl)
PE (1) PE20081665A1 (sl)
PL (1) PL2121630T3 (sl)
PT (1) PT2121630E (sl)
RS (1) RS52515B (sl)
SG (1) SG178779A1 (sl)
SI (1) SI2121630T1 (sl)
TW (1) TWI424847B (sl)
UA (1) UA97826C2 (sl)
UY (1) UY30910A1 (sl)
WO (1) WO2008098892A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
DE102007007440A1 (de) 2007-02-15 2008-08-21 Bayerische Motoren Werke Aktiengesellschaft Verfahren zur Steuerung und/oder Regelung der Verdampfertemperatur einer Klimaanlage in einem Kraftfahrzeug
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
PL2148873T3 (pl) 2007-04-23 2013-01-31 Janssen Pharmaceutica Nv Pochodne 4-alkoksypirydazynowe jako szybko dysocjujący antagoniści receptora dopaminowego 2
AU2009266001B2 (en) * 2008-07-03 2014-03-27 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009275887B2 (en) 2008-07-31 2013-06-20 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
CA2788355C (en) 2010-02-18 2018-03-06 Devi Reddy Gohimukkula Phenyl-heteroaryl derivatives and methods of use thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5461053A (en) 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
CA2176722A1 (en) 1993-12-28 1995-07-06 Ruth E. Ten Brink Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
SK1352000A3 (en) * 1997-08-15 2000-08-14 Pfizer Prod Inc 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
PT1379520E (pt) 2001-02-23 2006-08-31 Merck & Co Inc Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
DK1443046T3 (da) 2001-10-09 2009-04-14 Kyorin Seiyaku Kk Nye 4-(2-furoyl)-amino-piperidiner, mellemprodukter til deres syntese, fremgangsmåde til deres fremstilling og deres medicinske anvendelse
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
WO2003049736A1 (en) 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
AU2003213184A1 (en) 2002-02-22 2003-09-09 Pharmacia And Upjohn Company Pyridyl sulfone derivatives as 5-ht receptor antagonists
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
WO2004028520A1 (ja) 2002-09-26 2004-04-08 Mandom Corporation 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA05010081A (es) 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
EP1628626B2 (de) 2003-05-07 2013-12-04 OTC GmbH Zusammensetzungen zur gezielten freisetzung von duftstoffen und aromen
MXPA05012007A (es) 2003-05-08 2006-05-31 Kyorin Seiyaku Kk Compuesto de 4- (2-furoil) aminopiperidina util como agente terapeutico para el prurito.
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
DK1651615T3 (da) 2003-07-29 2010-05-25 High Point Pharmaceuticals Llc Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
TWI345974B (en) 2003-07-30 2011-08-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
US7300932B2 (en) 2003-08-07 2007-11-27 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
US7863044B2 (en) 2003-10-24 2011-01-04 Tao Cheng p18 in stem cell manipulations
CA2555227A1 (en) 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinone ureas as antagonists of .alpha.4 integrins
JP4627315B2 (ja) 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
EP1742932A1 (en) 2004-04-28 2007-01-17 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
KR20070034524A (ko) * 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2585172C (en) 2004-10-29 2014-08-12 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
EP1868652A2 (en) 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
WO2008019967A2 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
PL2148873T3 (pl) 2007-04-23 2013-01-31 Janssen Pharmaceutica Nv Pochodne 4-alkoksypirydazynowe jako szybko dysocjujący antagoniści receptora dopaminowego 2
EP2148872A1 (en) 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
WO2009037296A1 (en) * 2007-09-20 2009-03-26 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
AU2009266001B2 (en) 2008-07-03 2014-03-27 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists
AU2009275887B2 (en) 2008-07-31 2013-06-20 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists

Also Published As

Publication number Publication date
HRP20120876T1 (hr) 2012-11-30
MX2009008616A (es) 2009-08-20
US8791120B2 (en) 2014-07-29
CY1113759T1 (el) 2016-07-27
IL200310A (en) 2013-07-31
WO2008098892A1 (en) 2008-08-21
CN101605764B (zh) 2013-06-19
JP2010518051A (ja) 2010-05-27
BRPI0807492A2 (pt) 2014-05-27
PT2121630E (pt) 2012-11-02
ES2392470T3 (es) 2012-12-11
CN101605764A (zh) 2009-12-16
UY30910A1 (es) 2008-09-02
MY148899A (en) 2013-06-14
IL200310A0 (en) 2010-04-29
EP2121630A1 (en) 2009-11-25
EA200970760A1 (ru) 2009-12-30
AU2008214716A1 (en) 2008-08-21
AU2008214716B2 (en) 2013-05-09
JO2849B1 (en) 2015-03-15
EA017508B1 (ru) 2013-01-30
CA2674752A1 (en) 2008-08-21
CA2674752C (en) 2015-03-31
RS52515B (sr) 2013-04-30
EP2121630B1 (en) 2012-08-01
TWI424847B (zh) 2014-02-01
NZ578560A (en) 2010-12-24
PL2121630T3 (pl) 2012-12-31
KR20090129402A (ko) 2009-12-16
TW200902006A (en) 2009-01-16
KR101486408B1 (ko) 2015-01-27
DK2121630T3 (da) 2012-11-12
US20100069394A1 (en) 2010-03-18
AR065333A1 (es) 2009-06-03
CL2008000440A1 (es) 2008-08-22
US9422296B2 (en) 2016-08-23
JP5225292B2 (ja) 2013-07-03
UA97826C2 (ru) 2012-03-26
PA8768901A1 (es) 2008-11-19
US20140336381A1 (en) 2014-11-13
PE20081665A1 (es) 2008-11-22
SG178779A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
IL200310A0 (en) Fast dissociating dopamine 2 receptor antagonists
ZA200803668B (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
IL212545A0 (en) Toll-like receptor 3 antagonists
IL201663A0 (en) 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
PT1981902E (pt) Antagonistas dos recetores nogo
AP2008004602A0 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
LT2307374T (lt) Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai
IL206237A0 (en) Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
IL209264A0 (en) Heteroaromatic monoamides as orexinin receptor antagonists
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
ZA200906543B (en) Pyrimidinyl-piperazines useful as dopamine D3/D2 receptor ligands
PL2091938T3 (pl) Piperydynyloaminipirazyny i ich zastosowanie jako szybko dysocjujących antagonistów receptora dopaminy 2
IL201661A0 (en) Thia(dia) zoles as fast dissociating dopamine 2 receptor antagonists
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
IL201662A0 (en) Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
ZA200806992B (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
GB0701632D0 (en) MET receptor antagonists
ZA201103984B (en) Toll-like receptor 3 antagonists
HK1152719A (en) Somatostatin receptor 2 antagonists
GB0916792D0 (en) (1,4)-Benzodiazepines as vasopressin V2 receptor antagonists